
    
      This is a Phase 1 dose escalation study to assess the safety and tolerability of
      subcutaneously administered SDX-7320 in patients with advanced refractory or late-stage solid
      tumors.

      Once the MTD has been determined up to 12 patients will be treated at this dose level, to
      further characterize treatment emergent adverse events (TEAEs).
    
  